110 related articles for article (PubMed ID: 27247367)
21. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
Adackapara CA; Sholl LM; Barletta JA; Hornick JL
Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
[TBL] [Abstract][Full Text] [Related]
23. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.
Liu H; Li Z; Wang Y; Feng Q; Si L; Cui C; Guo J; Xue W
Pathol Int; 2014 Dec; 64(12):601-6. PubMed ID: 25359093
[TBL] [Abstract][Full Text] [Related]
25. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.
Guo X; Xu Y; Zhao Z
Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285
[TBL] [Abstract][Full Text] [Related]
26. Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma.
Manfredi L; Meyer N; Tournier E; Grand D; Uro-Coste E; Rochaix P; Brousset P; Lamant L
Acta Derm Venereol; 2016 Jun; 96(5):630-4. PubMed ID: 26695089
[TBL] [Abstract][Full Text] [Related]
27. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
28. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
[TBL] [Abstract][Full Text] [Related]
29. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
Wellbrock C; Marais R
J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
[TBL] [Abstract][Full Text] [Related]
30. An immunohistochemical comparison between MiTF and MART-1 with Azure blue counterstaining in the setting of solar lentigo and melanoma in situ.
Hillesheim PB; Slone S; Kelley D; Malone J; Bahrami S
J Cutan Pathol; 2011 Jul; 38(7):565-9. PubMed ID: 21362015
[TBL] [Abstract][Full Text] [Related]
31. The density and distribution of melanocytes adjacent to melanoma and nonmelanoma skin cancers.
Barlow JO; Maize J; Lang PG
Dermatol Surg; 2007 Feb; 33(2):199-207. PubMed ID: 17300606
[TBL] [Abstract][Full Text] [Related]
32. Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma.
Aksenenko MB; Kirichenko AK; Ruksha TG
Pathol Res Pract; 2015 Jul; 211(7):521-7. PubMed ID: 25888143
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
34. Melanoma Regression and Recurrence in Zebrafish.
Wojciechowska S; Zeng Z; Lister JA; Ceol CJ; Patton EE
Methods Mol Biol; 2016; 1451():143-53. PubMed ID: 27464806
[TBL] [Abstract][Full Text] [Related]
35. DMBT1 expression distinguishes anorectal from cutaneous melanoma.
Helmke BM; Renner M; Poustka A; Schirmacher P; Mollenhauer J; Kern MA
Histopathology; 2009 Jan; 54(2):233-40. PubMed ID: 19207948
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic features and immunohistochemical spectrum of 11 cases of epithelioid malignant peripheral nerve sheath tumors, including INI1/SMARCB1 results and BRAF V600E analysis.
Rekhi B; Kosemehmetoglu K; Tezel GG; Dervisoglu S
APMIS; 2017 Aug; 125(8):679-689. PubMed ID: 28452074
[TBL] [Abstract][Full Text] [Related]
37. A Case of Giant Primary Dermal Melanoma with BRAF V600E Mutation.
Imamura T; Nakamura Y; Teramoto Y; Sato S; Asami Y; Arai E; Yamamoto A
Acta Derm Venereol; 2016 Aug; 96(6):840-1. PubMed ID: 26984828
[No Abstract] [Full Text] [Related]
38. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
Kuan SF; Navina S; Cressman KL; Pai RK
Hum Pathol; 2014 Mar; 45(3):464-72. PubMed ID: 24529329
[TBL] [Abstract][Full Text] [Related]
40. Morphologic and Immunohistochemical Characteristics of Anorectal Melanoma.
Charifa A; Zhang X
Int J Surg Pathol; 2018 Dec; 26(8):725-729. PubMed ID: 29759015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]